Colman R W, Figures W R
Mol Cell Biochem. 1984;59(1-2):101-11. doi: 10.1007/BF00231307.
Adenosine diphosphate (ADP) is known to induce platelet shape change, aggregation and fibrinogen binding, followed by secretion. These processes are mediated by the binding of ADP to an externally oriented protein of the platelet plasma membrane. An affinity analog of ATP, a competitive inhibitor of the action of ADP, has been utilized to probe the structure and function of this receptor. FSBA (5'-p-fluorosulfonylbenzoyl adenosine) covalently modifies a single protein in intact platelets with Mr = 100 000 and concomitantly inhibits platelet shape change, aggregation and fibrinogen binding. Studies on platelet membranes demonstrate non-covalent association of ADP-binding protein with actin which is also labeled by FSBA but only in isolated membranes. This finding suggests a structural and functional coupling of the receptor to the contractile process. The putative ADP receptor covalently modified with FSBA is cleaved by chymotrypsin, a process that reverses the inability of the platelets to bind fibrinogen. Thus, the Mr = 100 000 polypeptide may be involved in the proteolytic exposure of fibrinogen binding sites on the platelet surface. The ability of FSBA to inhibit platelet aggregation and fibrinogen binding by prostaglandin H2 derivatives and epinephrine suggest that ADP is involved in these processes. However, the interaction is not at the receptor level since shape change, stimulated by PGH2 derivatives and yohimbine (epinephrine antagonist) binding are unaffected by FSBA. Finally, the action of ADP to inhibit PGE1- or PGI2-stimulated adenylate cyclase appears to be mediated by a receptor distinct for the protein modified by FSBA.
已知二磷酸腺苷(ADP)可诱导血小板形态改变、聚集以及纤维蛋白原结合,随后引发分泌。这些过程是由ADP与血小板质膜外向蛋白的结合介导的。一种ATP的亲和类似物,即ADP作用的竞争性抑制剂,已被用于探究该受体的结构和功能。5'-对氟磺酰苯甲酰腺苷(FSBA)可共价修饰完整血小板中一种分子量为100000的单一蛋白质,并同时抑制血小板形态改变、聚集以及纤维蛋白原结合。对血小板膜的研究表明,ADP结合蛋白与肌动蛋白存在非共价结合,肌动蛋白也可被FSBA标记,但仅在分离的膜中如此。这一发现提示该受体与收缩过程存在结构和功能上的偶联。用FSBA共价修饰的假定ADP受体可被胰凝乳蛋白酶切割,这一过程可逆转血小板无法结合纤维蛋白原的情况。因此,分子量为100000的多肽可能参与了血小板表面纤维蛋白原结合位点的蛋白水解暴露过程。FSBA抑制前列腺素H2衍生物和肾上腺素诱导的血小板聚集及纤维蛋白原结合的能力表明,ADP参与了这些过程。然而,这种相互作用并非发生在受体水平,因为前列腺素H2衍生物和育亨宾(肾上腺素拮抗剂)结合所刺激的形态改变不受FSBA影响。最后,ADP抑制前列腺素E1或前列环素刺激的腺苷酸环化酶的作用似乎是由一种与被FSBA修饰的蛋白不同的受体介导的。